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It is widely recognized that the earlier thrombolysis is administered after stroke onset, the better the outcome.1–5 
In stroke thrombolysis, onset to treatment time can be divided 
into onset-to-door and door-to-needle time (DNT). The latter 
can be influenced by streamlining of all parts of the in-hospital 
thrombolysis process and improves with center experience. 
Patients with longer DNTs have a lower chance of achieving 
an excellent outcome (a modified Rankin Scale score of 0 or 1) 
at 3 months.6
We first studied overall temporal changes in DNT in 
centers registering patients into the Safe Implementation 
of Thrombolysis in Stroke (SITS)-International Stroke 
Thrombolysis registry (ISTR),7 and we hypothesized that 
DNT is influenced by the center experience judged by the 
annual number of patients treated.
Patients and Methods
Study Setting
At the time of the data extraction, the SITS-ISTR was a collaboration 
of >750 clinical centers in >40 countries (45 079 patients). It includes 
data of unselected ischemic stroke patients treated with intravenous 
thrombolysis according to institutional guidelines. Its first part in-
cludes patients who were registered in the SITS monitoring study, 
which was required by the European Medicines Agency after granting 
of conditional license for alteplase in 2002. Details of the methods, 
management, and demographics of SITS can be found elsewhere.7,8 
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Ethical approvals for this study were obtained in countries in which 
they were required; other countries approved the register for conduct 
as an anonymized audit.
Year of treatment, DNT, and center codes were electronically 
 extracted from the SITS database. We also extracted sex, age, base-
line National Institutes of Health Stroke Scale (NIHSS), and history of 
diabetes mellitus, hypertension, atrial fibrillation, and previous stroke. 
We then identified the year when centers started registering patients 
into the SITS registry and looked in detail at those which started in the 
first 3 years, ie, between 2003 and 2005, in the middle (2006–2008), 
and in the last 3 years, ie, between 2009 and 2011. As an additional 
analysis, we analyzed effect of early registration of centers, for ex-
ample, within the first year (January 1, 2003 to December 31, 2003).
On the basis of the retrieved number of patients treated in the cen-
ters per year, we created 6 volume/y categories: <5, 5 to 24, 25 to 
49, 50 to 74, 75 to 99, and ≥100 treated patients/y. A center was at-
tributed to a volume/y category if it was in the category range at least 
for 3 subsequent years. We could not analyze the effect of the type of 
stroke center because primary, secondary, and tertiary stroke centers 
were not defined in 2002. Hence, each center was judged by how soon 
it started entering data into the SITS registry and by the number of 
patients treated annually. The center experience, however, was evalu-
ated by the annual volume of patients and not by the length of SITS 
membership. The latter does not necessarily reflect the experience be-
cause some dedicated stroke centers might have joined the SITS later. 
Nonetheless, there is one exception. The centers that joined the SITS 
registry during 2003 can be considered as the most experienced be-
cause the European Authorities granted conditional license for stroke 
thrombolysis with alteplase in 2002. One of the license conditions 
was that all patients treated with thrombolysis must be registered into 
the SITS registry; hence, the centers that joined during 2003 (no cen-
ter joined in 2002) were the centers with experience gained, for exam-
ple, from the randomized controlled trials. The centers that joined the 
SITS registry after 2003 implemented the thrombolysis protocol later.
Statistical Analyses
DNT had a non-normal distribution. Temporal changes in DNT 
among the subsequent years of registration adjusted for the effect 
of center volume were studied with a model of generalized estimat-
ing equations (scale response and γ with log-link model). The model 
included the following covariates and factors: age, baseline NIHSS, 
sex, and medical history. About the medical history, the percentages 
of the missing data were between 1.5% and 2% except for dyslipid-
emia (10%), which was excluded from the model. The center code 
was included as a within-subject effect (random) in the generalized 
estimating equations model; the option for correlation matrix in SPSS 
was exchangeable. We also included the interaction between center 
volume and year of treatment in the model. In the simple model, 
we only tested year of treatment, center volume, NIHSS, and age. 
Because age was not statistically significant (P=0.76), it was not 
included in more complex models with comorbidities. Statistical 
significance was set at 0.05 (2-tailed). Analyses were performed on 
IBM SPSS 22 (IBM Corp, Armonk, NY).
Results
Between December 2002 and December 2011, 45 079 patients 
were included in the SITS-ISTR. DNT was not registered for 
1.6% (720/45 079) of the patients. These were excluded from 
the analyses, and the final cohort size was 44 359 patients. 
Their median DNT was 67 (interquartile range, 47–91) min-
utes with a mean of 73 (SD, 37) minutes. The overall picture 
of DNT changes in the whole cohort and by volume category 
is shown in Figure 1A and 1B. Basic characteristics of the 
centers that joined the registry in one of the 3 periods (enroll-
ment periods: 2003–2005, 2006–2008, and 2009–2011) are 
shown in Table 1.
The results of the generalized estimating equations model 
are outlined in Table 2. After adjustment for sex, NIHSS, and 
comorbidity, we saw a robust effect on DNT caused by center 
volume and the enrollment period but a less robust effect of 
the treatment year (note the differences in both Wald χ2 and 
magnitude of β coefficients). The effect estimates are derived 
using a log-link function. For example, if we look at the effect 
of treatment year, every single minute of DNT in 2011 equals 
to 1.07 [exp(0.064)] minutes of DNT in 2003. So, a patient 
with DNT of 70 minutes in 2011 would have had DNT of 
74.6 minutes in 2003. As another example from Table 3, every 
minute of DNT in small centers (<5 patients/y) equals to 0.67 
[exp(-0.401)] minutes in large centers (≥100 patients/y). In 
line, a patient with DNT of 70 minutes in small centers would 
have had DNT of 47 minutes in large centers. Note that effect 
estimates of each individual variable are adjusted for all the 
other variables in the model. When adding the interaction 
between year of treatment and center volume into the model, 
we observed a significant interaction (P<0.001). However, the 
interaction was highly driven by large centers that joined the 
registry between 2003 and 2005. Results including the inter-
action are shown in Tables I and II in the online-only Data 
Supplement.
Because of the low number of cases in some of the volume 
categories (Table 1), we tested for the sensitivity of our main 
model (without interaction). For this purpose, we recoded the 
volume category, so that the largest category was set to >50 
patients/y. The results were in line with the original model 
Figure 1. Temporal changes in door-to-needle time (DNT and interquartile range) in all centers at the patient level (A) and the center level (B).
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with the only exception that DNT in 2003 was not signifi-
cantly different from 2011 (data not shown).
The temporal changes of DNT in patients from the centers 
that started within 2003 (21 countries, 137 centers, and 15 197 
patients) are shown in Figure 2. Their median DNT shortened 
from 72 to 59 minutes between 2003 and 2011. The overall 
median DNT of these centers was 62 (42–89) minutes when 
compared with 70 (50–93) minutes in the centers that joined 
after 2003. When we performed the generalized estimating 
equations model only with the centers that joined the regis-
try during 2003, we observed similar effect of center volume; 
however, the effect of year of treatment had a different profile 
(β coefficients and Wald χ2 in Table 3). Specifically, in these 
centers, DNT continuously declined until 2008 but then did 
not significantly change after 2008. For the comparison with 
the whole cohort (Table 2), DNT was the same in 2011 (the 
reference year) as it was in 2003 and 2004, with only mildly 
lower DNTs in years 2005 to 2010. Thus, those centers that 
joined the registry already in 2003 have reduced DNT over 
time, as evidenced by the 2003-only analysis (Table 3), but by 
including all centers, the change over time is attenuated.
Discussion
Thrombolysis is a complex intervention, which required reor-
ganization of services and specific staff training when it was 
first introduced. Achievement of fast DNTs is only possible 
with efficient and well-rehearsed internal processes. It is there-
fore expected that DTN improves with time as centers gain 
more experience. However, this study shows that DNT did 
not change much overall during the first decade of the SITS 
registry (2002–2011; Figure 1A). This is in line with the data 
from Get With The Guidelines program.9 The observed annual 
changes in DNT can be better explained by center volume 
than the year of treatment (Table 2). The most robust annual 
DNT changes were observed in centers that joined the SITS 
within the first year (2003; Figure 2; Table 3). Temporal DNT 
profile in these centers was different from the whole cohort 
(Tables 2 and 3), which suggests that their streamlining of the 
factors known to be associated with DNT was on a high level. 
In contrary, in centers that joined the SITS relatively late (after 
2009), there were no annual differences in DNT whatsoever. 
This might suggest that some of the learning from the early 
adopters was transferred to later registering centers and that 
the process rather than individual experience is a major factor.
Our observation of patient volume being the strongest 
determinant of DNT was reported also elsewhere.9 The effect 
of volume held true even in centers that joined the SITS reg-
istry after 2009. The most robust annual decrease in DNT was 
observed in centers with high volume of patients (≥100/y and 
75–99/y; Tables 2 and 3) even when adjusting for the inter-
action between center volume and year of treatment (arising 
Table 1. Basic Characteristics Based on Period of Joining the 
Registry
Centers Joined in 
2003–2005
Centers Joined in 
2006–2008
Centers Joined in 
2009–2011
DNT, min 65 (46–90) 68 (50–92) 72 (51–98)
Age, y 70 (61–77) 69 (59–76) 70 (60–77)
Women, % 43 42 44
Baseline NIH Stroke 
Scale
12 (7–17) 12 (7–17) 12 (7–17)
Diabetes mellitus, % 17.4 16.3 18.4
Hypertension, % 64.0 62.4 65.5
Atrial fibrillation, % 25.5 23.7 25.5
Previous stroke, % 13.3 13.0 12.2
No. of countries 28 29 26
No. of centers 379 243 131
Total no. of patients 32 182 9356 2821
No. of centers/patients per volume category
  <5 patients/y 239/8030 147/1831 110/1341
  5–24 patients/y 88/7625 83/4639 19/951
  25–49 patients/y 32/6619 11/2091 0
  50–74 patients/y 11/3820 1/379 1/203
  75–99 patients/y 5/2542 1/416 0
  ≥100 patients/y 4/3546 0 1/326
If not otherwise stated, the data are presented as median (interquartile range). 
DNT indicates door-to-needle time; and NIH, National Institutes of Health.
Table 2. Generalized Estimating Equations Model for the 
Whole Cohort
Parameter β SE Wald χ2 P Value
Year
  2003 0.064 0.018 12.0 <0.01
  2004 0.027 0.014 3.5 0.06
  2005 −0.035 0.012 7.9 <0.01
  2006 −0.044 0.012 13.5 <0.001
  2007 −0.025 0.012 4.7 <0.05
  2008 −0.038 0.011 11.5 <0.01
  2009 −0.043 0.011 16.6 <0.001
  2010 −0.035 0.010 11.6 <0.01
  2011    Reference
Volume
  ≥100 patients/y −0.345 0.014 612.8 <0.001
  75–99 patients/y −0.089 0.012 60.8 <0.001
  50–74 patients/y 0.050 0.010 26.7 <0.001
  25–49 patients/y 0.037 0.008 21.0 <0.001
  5–24 patients/y 0.097 0.007 190.7 <0.001
 <5 patients/y    Reference
Factor
  Baseline NIHSS −0.002 0.001 15.0 <0.001
  Female sex 0.019 0.005 13.8 <0.001
  Diabetes mellitus 0.009 0.007 1.9 0.17
  Hypertension 0.026 0.005 22.8 <0.001
  Atrial fibrillation 0.011 0.006 3.3 0.07
  Previous stroke 0.029 0.008 14.7 <0.001
Joined 2003–2005 −0.077 0.011 45.6 <0.001
Joined 2006–2008 −0.087 0.012 56.1 <0.001
Joined 2009–2011    Reference
Positive values of β coefficient means longer and negative values shorter 
door-to-needle times. Note the magnitude of β coefficients and Wald χ2. NHISS 
indicates National Institutes of Health Stroke Scale.
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mostly from large centers that joined the registry between 2003 
and 2005: Tables I and II in the online-only Data Supplement). 
In most centers, DNT tended to rise after 2009/2010, except 
for centers treating ≥100 patients/y (Figures 1 and 2). This 
increase of DNT observed after 2009 can be perhaps explained 
by publication of the European Cooperative Acute Stroke 
Study (ECASS)-III trial and SITS-ISTR study at the end of the 
year 2008,10,11 which led to extension of the time window for 
stroke thrombolysis from 3 to 4.5 hours. The implementation 
of the extended time window followed gradually in different 
countries and centers. Evidence from UK SITS patients sug-
gests that extension of the time window led to treatment of 
more patients who may otherwise have missed the window for 
treatment, but also possibly a relaxation of urgency,12 which 
was also shown in our recent analysis.13 In contrast, Messé et 
al14 found that publication of the ECASS-III trial did not lead 
to longer DNT in Get With The Guidelines.
Taken together, our data confirmed that experience is more 
robustly linked to high annual volume of patients than to the 
year of treatment. Such effect of volume is not only unique for 
stroke thrombolysis9,15 but is also seen in other scenarios.16–19 
We have recently described measures that led to reduction 
of DNT in the Helsinki Center,20,21 where the current median 
DNT is 20 minutes. In the Barnes-Jewish Hospital in St. Louis, 
reduction of DNT was achieved after implementation of value 
stream analysis of Toyota’s lean manufacturing principles.22 In 
this study, we observed that DNT was associated with annual 
volume of patients, sex, history of hypertension and previous 
stroke, and baseline NIHSS, findings similar to Get With The 
Guidelines.9 In another analysis of Get With The Guidelines, 
Xian et al23 reported 3 hospital strategies independently asso-
ciated with lower DNT: rapid triage/stroke team notification, 
single-call activation system, and tissue-type plasminogen 
activator stored in the emergency department.
Results of the study presented here suggest that learning and 
experience in delivering thrombolysis in a timely fashion are 
transferrable. Also, many centers have made little progress in 
reducing DNT during the past 10 years. On the basis of these 
findings, we decided to launch a global project aiming to reduce 
DNT: Reduction of In-hospital Delays in Stroke Thrombolysis 
(SITS-WATCH). In the pilot phase of the project, we sent an 
itemized questionnaire to the SITS centers. This pilot phase 
helped us to understand the local situation and to recognize the 
factors prolonging DNT in the SITS centers. In the next phase, 
we sent specific tasks to the participating centers, via imple-
mentation of which it is possible to reduce DNT. Clearly, fac-
tors like rural versus urban, academic versus community-based, 
public versus private settings, availability of neurological and 
radiological expertise, level of emergency medical services 
expertise, prenotification, and many others do most probably 
play a role. The SITS-WATCH project is registered under its 
name at http://www.clinicaltrials.gov (NCT01811901). A simi-
lar initiative Target: Stroke is organized by the American Heart 
Association/American Stroke Association.24
Our study has limitations. We did not extract safety data 
(symptomatic intracranial hemorrhage) for the purpose 
of this study. However, safety data were described in other 
SITS publications.25 In the Helsinki center, the continuous 
decline in DNT was achieved without an increase in the rate 
of hemorrhagic complications.20 Furthermore, we do not pres-
ent any outcome data, as relationship between shorter treat-
ment delays and better functional outcome was addressed 
elsewhere.1,3,4 Our data come mostly from European centers, 
which is an important issue on generalizability of our findings 
to other countries with varying systems of stroke care. Last 
but not least, the SITS registry includes patients based on vol-
untary registration of participating centers, which might have 
caused a selection/referral bias.
Figure 2. Temporal changes in door-to-needle time (DNT and 
interquartile range) in centers that started registration within 2003 
at the center level.
Table 3. Generalized Estimating Equations Model for the 
Centers That Joined During 2003
Parameter β SE Wald χ2 P Value
Year
  2003 0.241 0.027 79.4 <0.001
  2004 0.189 0.026 52.8 <0.001
  2005 0.113 0.024 21.7 <0.001
  2006 0.081 0.025 10.3 <0.01
  2007 0.116 0.025 21.2 <0.001
  2008 0.019 0.026 0.6 0.46
  2009 0.027 0.025 1.2 0.27
  2010 0.038 0.025 2.2 0.14
  2011    Reference
Volume
  ≥100 patients/y −0.401 0.021 349.5 <0.001
  75–99 patients/y −0.109 0.021 27.7 <0.001
  50–74 patients/y 0.277 0.017 282.5 <0.001
  25–49 patients/y 0.183 0.013 186.4 <0.001
  5–24 patients/y 0.178 0.014 158.0 <0.001
  <5 patients/y    Reference
Factor
  Baseline NIHSS −0.003 0.001 8.3 <0.01
  Female sex 0.019 0.009 3.9 <0.05
  Diabetes mellitus 0.001 0.013 0.01 0.94
  Hypertension 0.013 0.010 1.7 0.19
  Atrial fibrillation 0.011 0.011 1.0 0.32
  Previous stroke 0.031 0.013 5.7 0.02
Positive values of β coefficient means longer and negative values shorter 
door-to-needle times. Note the magnitude of β coefficients and Wald χ2. NHISS 
indicates National Institutes of Health Stroke Scale.
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To conclude, only minor overall improvements in DNT 
were observed during the first decade of the SITS registry. 
About experience, center volume is more important than the 
year of treatment. Hence, a multicenter project to reduce DNT 
focusing mostly on the centers with lower annual volume is 
warranted. We think such a project is feasible. As an example, 
the Helsinki experience was used in the Melbourne center, 
where the in-hours median DNT dropped from 43 (33–59) 
minutes to 25 (19–48) minutes in 4 months after implementa-
tion of the changes.26 Because Melbourne is a single and a 
dedicated stroke center and we do not have the data on DNT in 
centers not participating in the SITS, we cannot anticipate that 
DNT would fall to such low levels in other centers. Substantial 
changes can nonetheless be achieved.
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SUPPLEMENTAL MATERIAL
Trends in door-to-thrombolysis delays in the SITS registry: effect of center volume and duration
of registry membership
1Daniel Strbian, MD, PhD, MSc (Stroke Med), FESO; 2Niaz Ahmed, MD, PhD; 2Nils Wahlgren, MD,
PhD; 3Kennedy R Lees, MD FRCP; 4Danilo Toni, MD, PhD, FESO; 5Christine Roffe, MD; 6Ida L
Surakka, MSc; 1Turgut Tatlisumak, MD, PhD, on behalf of the SITS Investigators
Departments of Neurology, 1Helsinki University Central Hospital, Helsinki, Finland and 2Karolinska
University Hospital, Stockholm, Sweden,3Institute of Cardiovascular & Medical Sciences, University
of Glasgow, Glasgow, UK, 4Emergency Department Stroke Unit, Department of Neurology and
Psychiatry, Policlinico Umberto I Hospital, “Sapienza” University of Rome, Rome, Italy, and
5University Hospital of North Staffordshire, Stoke-on-Trent, UK; 6Institute for Molecular Medicine
Finland, University of Helsinki, Finland
Supplementary Table I. Test of model effects when including interaction between center volume
and year of treatment
Parameter Robust Wald χ2 degree of
freedom
P-value
Year of treatment 141.56 8 <0.001
Center volume 974.76 5 <0.001
Female gender 19.91 1 <0.001
Diabetes mellitus 2.51 1 0.11
Hypertension 32.84 1 <0.001
Atrial fibrillation 4.09 1 <0.05
previous stroke 16.56 1 <0.001
baseline NIHSS 13.08 1 <0.001
center volume*year of
treatment interaction
588.62 40 <0.001
Supplementary Table II. Parameter estimates from the interaction model
Parameter B Standard error p-value
Year 2003 -0.115 0.029 <0.001
Year 2004 -0.134 0.024 <0.001
Year 2005 -0.154 0.023 <0.001
Year 2006 -0.181 0.024 <0.001
Year 2007 -0.117 0.025 <0.001
Year 2008 -0.055 0.028 <0.05
Year 2009 -0.006 NA NA
Year 2010 -0.009 NA NA
Year 2011 Reference
< 5 patients / year Reference
5-24 patients / year 0.018 0.024 0.47
25-49 patients / year -0.085 NA NA
50-74 patients / year 0.062 0.033 0.059
75-99 patients / year -0.090 0.044 <0.05
≥ 100 patients / year -0.771 0.041 <0.001
baseline NIHSS -0.002 0.0005 <0.001
female gender 0.020 0.005 <0.001
Diabetes mellitus 0.010 0.007 0.113
Hypertension 0.026 0.005 <0.001
Atrial fibrillation 0.012 0.006 <0.05
Previous stroke 0.031 0.008 <0.001
INTERACTIONS
≥ 100 patients*2003 0.621 0.073 <0.001
≥ 100 patients*2004 0.716 0.064 <0.001
≥ 100 patients*2005 0.477 0.057 <0.001
≥ 100 patients*2006 0.505 0.058 <0.001
≥ 100 patients*2007 0.502 0.056 <0.001
≥ 100 patients*2008 0.389 0.056 <0.001
≥ 100 patients*2009 0.323 NA NA
≥ 100 patients*2010 0.214 NA NA
≥ 100 patients*2011 Reference
75-99 patients*2003 0.372 0.098 <0.001
75-99 patients*2004 0.102 0.073 0.16
75-99 patients*2005 0.109 0.059 0.063
75-99 patients*2006 0.078 0.054 0.15
75-99 patients*2007 -0.060 0.054 0.27
75-99 patients*2008 -0.092 0.054 0.09
75-99 patients*2009 -0.164 NA NA
75-99 patients*2010 -0.141 NA NA
75-99 patients*2011 Reference
50-74 patients*2003 0.232 0.059 <0.001
50-74 patients*2004 0.104 0.046 <0.05
50-74 patients*2005 0.049 0.045 0.27
50-74 patients*2006 0.049 0.041 0.24
50-74 patients*2007 -0.069 0.041 0.09
50-74 patients*2008 -0.109 0.042 <0.01
50-74 patients*2009 -0.179 NA NA
50-74 patients*2010 -0.140 NA NA
50-74 patients*2011 Reference
25-49 patients*2003 0.362 NA NA
25-49 patients*2004 0.308 NA NA
25-49 patients*2005 0.250 NA NA
25-49 patients*2006 0.207 NA NA
25-49 patients*2007 0.158 NA NA
25-49 patients*2008 -0.010 NA NA
25-49 patients*2009 -0.027 NA NA
25-49 patients*2010 -0.025 NA NA
25-49 patients*2011 Reference
5-24 patients*2003 0.091 0.050 0.068
5-24 patients*2004 0.139 0.037 <0.001
5-24 patients*2005 0.090 0.031 <0.01
5-24 patients*2006 0.129 0.031 <0.001
5-24 patients*2007 0.047 0.031 0.12
5-24 patients*2008 0.002 0.032 0.96
5-24 patients*2009 -0.057 NA NA
5-24 patients*2010 -0.015 NA NA
5-24 patients*2011 Reference
<5*for all years References
Note: In the presence of interaction term, the marginal effect estimates for center volume
and year of treatment cannot be directly converted into time units.
NA: Could not estimate due to low number of observations per category.
